##ANALYSISTYPE=CFDNA
##PIPELINE=megSAP 2025_10-79-gaaed1599
##GENOME_BUILD=GRCh38
##CREATION_DATE=2025-09-03
##CALLING_DATE=04/0-8/-2021
##FILTER=Clustered_Variant=Clustered variants
##FILTER=Error=Alternative counts inside the expected error rate distribution
##FILTER=FDR=no description available
##FILTER=Fisher_Strand=Strand bias based on fisher test
##FILTER=LC_Downstream=Low complexity region (5bps) downstream. ≥ 80% of bases show the same nucleotide  or tandem of ≥ 3 equal nucleotides in a row
##FILTER=LC_Upstream=Low complexity region (5bps) upstream. ≥ 80% of bases show the same nucleotide or tandem of ≥ 3 equal nucleotides in a row
##FILTER=Low_AC=Less than defined minimum of alternative counts
##FILTER=Low_Complexity=no description available
##FILTER=low_conf_region=Variant marked as 'low_conf_region'.
##FILTER=Low_COV=Low coverage
##FILTER=Low_qual_pos=Position enriched with too many low quality bases
##FILTER=off-target=Variant marked as 'off-target'.
##FILTER=PASS=Passed filter
##FILTER=Strand_imbalanced=All alternative reads found in only one strand
##FILTER=Variant_Contamination=no description available
##FILTER=Variant_contamination=Reads supporting other alleles outside of the error rate distribution
##SAMPLE=<ID=DXcf000001_01,Gender=n/a,ExternalSampleName=cfDNA,IsTumor=yes,IsFFPE=no,DiseaseGroup=n/a,DiseaseStatus=n/a>
##DESCRIPTION=filter=Annotations for filtering and ranking variants.
##DESCRIPTION=quality=Quality parameters - variant quality (QUAL), depth (DP), quality divided by depth (QD), allele frequency (AF), mean mapping quality of alternate allele (MQM), probability of strand bias for alternate bases as phred score (SAP), probability of allele ballance as phred score (ABP)
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=regulatory=Regulatory consequence details.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD project.
##DESCRIPTION=gnomAD_sub=Sub-population allele frequenciens (AFR,AMR,EAS,NFE,SAS) in gnomAD project.
##DESCRIPTION=gnomAD_hom_hemi=Homoyzgous/hemizygous case count of gnomAD project (genome data).
##DESCRIPTION=gnomAD_het=Heterozygous allele count of the gnomAD project (genome data).
##DESCRIPTION=gnomAD_wt=Wildtype allele count of the gnomAD project (genome data).
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 10-20.
##DESCRIPTION=REVEL=REVEL pathogenicity prediction score. Deleterious threshold > 0.5.
##DESCRIPTION=AlphaMissense=AlphaMissense pathogenicity score. Deleterious threshold > 0.564.
##DESCRIPTION=MaxEntScan=MaxEntScan reference score and alternate score for (1) native splice site, (2) acceptor gain and (3) donor gain. Comma-separated list if there are different predictions for several transcripts.
##DESCRIPTION=SpliceAI=SpliceAI prediction. These include delta scores (DS) and delta positions (DP) for acceptor gain (AG), acceptor loss (AL), donor gain (DG), and donor loss (DL). Format: GENE|DS_AG|DS_AL|DS_DG|DS_DL|DP_AG|DP_AL|DP_DG|DP_DL.
##DESCRIPTION=PubMed=PubMed ids to publications on the given variant.
##DESCRIPTION=NGSD_som_c=Somatic variant count in the NGSD (tumor-normal).
##DESCRIPTION=NGSD_som_p=Project names containing this somatic variant in the NGSD (tumor-normal).
##DESCRIPTION=NGSD_som_to_c=Somatic variant count in the NGSD (tumor-only).
##DESCRIPTION=NGSD_som_vicc_interpretation=Somatic variant interpretation according VICC standard in the NGSD.
##DESCRIPTION=NGSD_som_vicc_comment=Somatic VICC interpretation comment in the NGSD.
##DESCRIPTION=NGSD_hom=Homozygous variant count in NGSD.
##DESCRIPTION=NGSD_het=Heterozygous variant count in NGSD.
##DESCRIPTION=NGSD_mosaic=Mosaic variant count in NGSD.
##DESCRIPTION=NGSD_group=Homozygous / heterozygous variant count in NGSD with the same disease group.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validation=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Variant comments from the NGSD.
##DESCRIPTION=gene_info=Gene information from NGSD (inheritance mode, gnomAD o/e scores).
##DESCRIPTION=CMC_genes=Gene symbol from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_MUTATION_ID=COSV identifier of variant from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_disease=diseases with > 1% of samples mutated where disease = Primary site(tissue) / Primary histology / Sub-histology = Samples mutated / Samples tested = Frequency from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_DNDS_ratio=diseases with significant dn/ds ratio (q-value < 5%) from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_mutation_significance=Significance tier of the variant from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CANCERHOTSPOTS_AA_CHANGE=Amino acid change as in original cancerhotspots.org file
##DESCRIPTION=CANCERHOTSPOTS_TOTAL_MUT=Total mutation count in cancerhotspots.org at certain amino acid position.
##DESCRIPTION=CANCERHOTSPOTS_ALT_COUNT=Count of specific amino acid alteration at same position in cancerhotspots.org.
##FILTER=low_conf_region=Low confidence region for small variant calling based on gnomAD AC0/RF filters and IMGAG trio/twin data.
##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample DXcf000001_01).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample DXcf000001_01).
##DESCRIPTION=p-value=Uncorrected p-value
##DESCRIPTION=m_AF=Multi-UMI alternative allele fraction
##DESCRIPTION=m_REF=Multi-UMI reference-like read counts
##DESCRIPTION=m_ALT=Multi-UMI alternative read counts
##DESCRIPTION=Strand=Alleles in strands: Alternative forward, Alternative reverse, Reference forward, Reference reverse
##DESCRIPTION=Sequence context=Sequence +/- 5bp around the variant.
##DESCRIPTION=Homopolymer=Indicates if variant is in a homopolymer region.
#chr	start	end	ref	obs	tumor_af	tumor_dp	p-value	Alt counts	m_AF	m_REF	m_ALT	Strand	Sequence context	Homopolymer	filter	quality	gene	variant_type	coding_and_splicing	regulatory	OMIM	ClinVar	HGMD	RepeatMasker	dbSNP	gnomAD	gnomAD_sub	gnomAD_hom_hemi	gnomAD_het	gnomAD_wt	phyloP	CADD	REVEL	AlphaMissense	MaxEntScan	SpliceAI	PubMed	NGSD_som_c	NGSD_som_p	NGSD_som_to_c	NGSD_som_vicc_interpretation	NGSD_som_vicc_comment	NGSD_hom	NGSD_het	NGSD_mosaic	NGSD_group	classification	classification_comment	validation	comment	gene_info	CMC_genes	CMC_MUTATION_ID	CMC_disease	CMC_DNDS_ratio	CMC_mutation_significance	CANCERHOTSPOTS_AA_CHANGE	CANCERHOTSPOTS_TOTAL_MUT	CANCERHOTSPOTS_ALT_COUNT
chr1	13828872	13828872	C	T	0.0016	5	2.40e-04	3164	0.00114	2630	3	3-2-1536-1623	CTGTACGTGTG	false	off-target	QUAL=36										0.00003		0,			-2.4550	0.35						0		0			0	0	0	0 / 0					PRDM2 (inh=n/a oe_syn=1.14 oe_mis=0.90 oe_lof=0.12)								
chr1	13828907	13828907	G	A	0.7371	2288	0.00e+00	3104	0.73362	683	1881	1111-1177-391-425	CACACGTACAG	false		QUAL=255										0.54186		4616,			-1.1070	0.59						0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					PRDM2 (inh=n/a oe_syn=1.14 oe_mis=0.90 oe_lof=0.12)								
chr2	106122379	106122379	A	G	0.4887	1142	0.00e+00	2337	0.49284	956	929	589-553-626-569	CAGAGATAAGA	false		QUAL=255										0.45336		3142,			-1.0090	1.66				UXS1|0.00|0.01|0.00|0.00|-1|-12|-12|8		0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					UXS1 (inh=n/a oe_syn=1.05 oe_mis=0.62 oe_lof=0.35)								
chr2	106122425	106122425	G	A	0.2137	616	0.00e+00	2882	0.20734	1858	486	390-226-1362-904	CAGCAGCACAG	false	off-target	QUAL=255															0.3620	1.86				UXS1|0.00|0.00|0.00|0.00|-40|48|19|-38		0		0			0	0	0	0 / 0					UXS1 (inh=n/a oe_syn=1.05 oe_mis=0.62 oe_lof=0.35)								
chr2	181548511	181548511	C	T	0.4795	1330	0.00e+00	2774	0.47672	1169	1065	687-643-778-666	AGATACAGGTT	false	off-target	QUAL=255										0.16820		506,			-9.3070	0.08				CERKL|0.00|0.00|0.00|0.00|34|37|30|34		0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					CERKL (inh=AR oe_syn=0.98 oe_mis=1.04 oe_lof=1.16)								
chr3	179218303	179218303	G	A	0.0192	60	1.50e-11	3125	0.01886	2497	48	31-29-1517-1547	TCACTGAGCAG	false		QUAL=108						13655 [pathogenic/likely pathogenic DISEASE=Hepatocellular carcinoma,Abnormality of cardiovascular system morphology,Pancreatic adenocarcinoma,Transitional cell carcinoma of the bladder,Neoplasm of stomach,Breast neoplasm,Brainstem glioma,Carcinoma of esophagus,Renal cell carcinoma, papillary, 1,Malignant melanoma of skin,Lung adenocarcinoma,Small cell lung carcinoma,Non-small cell lung cancer,Squamous cell lung carcinoma,Neoplasm of brain,Seborrheic keratosis,Sarcoma,Neoplasm of ovary,Nasopharyngeal Neoplasms,Neoplasm of the large intestine,Carcinoma of colon,Carcinoma of gallbladder,Breast adenocarcinoma,Adenocarcinoma of stomach,Adenocarcinoma of prostate,Gallbladder cancer,Ovarian Serous Cystadenocarcinoma,Uterine Carcinosarcoma,Squamous cell carcinoma of the head and neck,Megalencephaly-capillary malformation-polymicrogyria syndrome,Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi,Glioblastoma,Neoplasm of uterine cervix,Papillary renal cell carcinoma, sporadic,Malignant neoplasm of body of uterus,OVARIAN CANCER, EPITHELIAL, SOMATIC,PIK3CA related overgrowth spectrum,not provided];	CM126692 [CLASS=DM MUT=ALT PHEN="Megalencephaly-capillary malformation" GENE=PIK3CA];								9.6020	30.00				PIK3CA|0.00|0.00|0.00|0.00|3|6|35|31		37	PATHO_Somatic,SomaticAndTreatment,Vak-Heilversuche,eMed-HCC	0	ONCOGENIC		0	0	n/a	0 / 0					PIK3CA (inh=AR+AD oe_syn=0.78 oe_mis=0.34 oe_lof=0.05)	PIK3CA	COSV55873239	stomach/carcinoma/adenocarcinoma=51/3303=1.54%;endometrium/carcinoma/mixed_serous_and_endometrioid_carcinoma=4/85=4.71%;penis/carcinoma/squamous_cell_carcinoma=8/185=4.32%;breast/carcinoma/ER-PR-HER-positive_carcinoma=7/55=12.73%;soft_tissue/Overgrowth_syndrome/CLOVES_syndrome=7/47=14.89%;ovary/germ_cell_tumour/teratoma=13/55=23.64%;vulva/carcinoma/squamous_cell_carcinoma=11/125=8.8%;breast/carcinoma/ER-positive_carcinoma=128/1587=8.07%;ovary/carcinoma/endometrioid_carcinoma=7/326=2.15%;breast/carcinoma/hormone_receptor-positive_carcinoma=27/328=8.23%;vulva/in_situ_neoplasm/vulvar_intraepithelial_neoplasia=5/11=45.45%;breast/carcinoma/ductolobular_carcinoma=15/132=11.36%;cervix/carcinoma/endocervical_adenocarcinoma=6/62=9.68%;skin/other/seborrhoeic_keratosis=4/259=1.54%;cervix/carcinoma/small_cell_carcinoma=4/18=22.22%;breast/carcinoma_in_situ/ductal_carcinoma_in_situ=8/612=1.31%;cervix/carcinoma/adenocarcinoma=9/309=2.91%;cervix/in_situ_neoplasm/cervical_intraepithelial_neoplasia_Grade_III=6/290=2.07%;penis/carcinoma/NS=4/28=14.29%;breast/carcinoma/luminal_B_carcinoma=5/86=5.81%;gastrointestinal_tract_(site_indeterminate)/carcinoma/adenocarcinoma=7/477=1.47%;thyroid/carcinoma/anaplastic_carcinoma=13/862=1.51%;cervix/carcinoma/squamous_cell_carcinoma=83/1021=8.13%;large_intestine/carcinoma/adenocarcinoma=708/20968=3.38%;oesophagus/carcinoma/adenocarcinoma=9/815=1.1%;breast/carcinoma/basal_(triple-negative)_carcinoma=43/932=4.61%;breast/carcinoma/lobular_carcinoma=51/604=8.44%;oesophagus/carcinoma/NS=11/386=2.85%;oesophagus/carcinoma/squamous_cell_carcinoma=52/2556=2.03%;stomach/carcinoma/NS=6/559=1.07%;urinary_tract/carcinoma/transitional_cell_carcinoma=147/1805=8.14%;biliary_tract/carcinoma/NS=8/318=2.52%;salivary_gland/carcinoma/salivary_duct_carcinoma=13/160=8.13%;stomach/carcinoma/diffuse_adenocarcinoma=6/202=2.97%;upper_aerodigestive_tract/carcinoma/NS=7/369=1.9%;lung/carcinoma/NS=7/318=2.2%;breast/carcinoma/ER-PR-positive_carcinoma=28/656=4.27%;large_intestine/carcinoma/squamous_cell_carcinoma=20/215=9.3%;breast/carcinoma/NS=346/9998=3.46%;lung/carcinoma/squamous_cell_carcinoma=55/2832=1.94%;upper_aerodigestive_tract/carcinoma/nasopharyngeal_carcinoma=13/657=1.98%;ovary/carcinoma/clear_cell_carcinoma=24/763=3.15%;upper_aerodigestive_tract/carcinoma/squamous_cell_carcinoma=130/3681=3.53%;central_nervous_system/glioma/oligodendroglioma_Grade_III=6/202=2.97%;breast/carcinoma/ductal_carcinoma=205/5021=4.08%;urinary_tract/carcinoma/NS=53/818=6.48%;breast/carcinoma/luminal_NS_carcinoma=28/254=11.02%;endometrium/carcinoma/endometrioid_carcinoma=43/1964=2.19%;stomach/carcinoma/intestinal_adenocarcinoma=6/311=1.93%	cervical=1.21e-47;glioma=7.08e-08;breast=1.04e-96;colon=5.32e-71;NSCLC=6.07e-30;bladder=6.95e-26;gastric=3.17e-27;HNSCC=2.01e-40;endometrioid=1.99e-27	1			
chr4	153888555	153888555	G	C	0.2309	769	0.00e+00	3331	0.23527	2090	643	414-355-1257-1305	AGACAGAGAGT	false		QUAL=255										0.46706		3478,			0.8470	4.88						0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)													
chr4	168742464	168742464	T	G	0.4826	1426	0.00e+00	2955	0.47953	1246	1148	694-732-762-767	TAAAGTGTTAT	false	Clustered_Variant	QUAL=255										0.52203		4249,			-0.0450	2.68				PALLD|0.00|0.01|0.00|0.00|0|38|0|-13		2	PATHO_Somatic	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					PALLD (inh=AD oe_syn=0.91 oe_mis=0.90 oe_lof=0.35)								
chr6	152376571	152376571	C	T	0.2356	704	0.00e+00	2988	0.22980	1897	566	348-356-1096-1188	GGTGACGCAAA	false		QUAL=255						262202 [benign DISEASE=Spinocerebellar ataxia, autosomal recessive 8,Emery-Dreifuss muscular dystrophy 4, autosomal dominant,not specified];				0.50035		3955,			0.5590	6.39						1	SomaticAndTreatment	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					SYNE1 (inh=AR+AD oe_syn=1.05 oe_mis=1.01 oe_lof=0.37):SYNE1-AS1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)								
chr7	55174772	55174786	GGAATTAAGAGAAGC	-	0.0064	28	2.95e-08	4364	0.00622	3513	22	13-15-2172-2164	TATCAAGGAAT	false		QUAL=75						163343 [drug response DISEASE=Tyrosine kinase inhibitor response];									9.8920	22.10				EGFR|0.00|0.00|0.06|0.00|-47|-49|-31|49		0		0			0	0	0	0 / 0					EGFR (inh=AR oe_syn=1.13 oe_mis=0.80 oe_lof=0.23):EGFR-AS1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)	EGFR	COSV51765119	lung/carcinoma/adenocarcinoma=524/49215=1.06%;lung/carcinoma/mixed_adenosquamous_carcinoma=25/746=3.35%;lung/carcinoma/non_small_cell_carcinoma=533/35864=1.49%;lung/other/hyperplasia=10/138=7.25%;lung/carcinoma/bronchioloalveolar_adenocarcinoma=30/1081=2.78%		Other			
chr7	55181305	55181305	-	TGGCCAGCG	0.0046	21	8.74e-06	4573	0.00399	3744	15	17-4-2202-2347	ACGTGATGGCC	false	Variant_Contamination	QUAL=50						177678 [drug response DISEASE=Tyrosine kinase inhibitor response];														EGFR|0.01|0.00|0.00|0.00|-8|-12|0|2		0		0			0	0	0	0 / 0					EGFR (inh=AR oe_syn=1.13 oe_mis=0.80 oe_lof=0.23):EGFR-AS1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)								
chr7	137345092	137345092	T	C	0.4352	2240	0.00e+00	5147	0.43979	2233	1753	1223-1017-1550-1357	ACTTCTGTGTG	false		QUAL=255										0.56297		4991,			-1.4950	5.85						3	PATHO_Somatic	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					PTN (inh=n/a oe_syn=0.89 oe_mis=0.65 oe_lof=0.47)								
chr7	150742412	150742412	C	T	0.4506	2270	0.00e+00	5038	0.45315	2241	1857	1117-1153-1386-1382	CAGGCCGATAC	false		QUAL=255										0.39655		2694,			-3.4450	1.26				GIMAP1-GIMAP5|0.00|0.02|0.00|0.00|22|-2|-2|14,GIMAP5|0.00|0.02|0.00|0.00|22|-2|-2|14		2	I16R041,eMed-HCC	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					GIMAP5 (inh=n/a oe_syn=1.18 oe_mis=1.12 oe_lof=0.90)	GIMAP5	COSV57529710			Other			
chr8	28553555	28553555	T	C	0.7473	2173	0.00e+00	2908	0.75042	590	1774	1037-1136-345-390	TGAAGTTTTCC	false	Low_Complexity	QUAL=255										0.58081		5363,			-0.2110	2.50				FZD3|0.00|0.00|0.00|0.00|12|0|23|-2		0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					FZD3 (inh=n/a oe_syn=0.97 oe_mis=0.62 oe_lof=0.37)								
chr9	128261226	128261226	T	C	0.3731	1496	1.16e-57	4010	0.36708	2088	1211	803-693-1266-1247	ACTCATGCTAC	false		QUAL=255										0.09101		462,			-3.7650	0.04				GOLGA2|0.00|0.00|0.01|0.00|27|33|1|34		0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					GOLGA2 (inh=n/a oe_syn=0.92 oe_mis=0.89 oe_lof=0.18)								
chr9	128261237	128261237	T	-	0.0015	6	1.30e-02	3968	0.00031	3275	1	2-4-2041-1921	CATTCCTTCTC	false	FDR;off-target	QUAL=18															2.1320					GOLGA2|0.00|0.01|0.00|0.00|17|50|-18|0		0		0			0	0	0	0 / 0					GOLGA2 (inh=n/a oe_syn=0.92 oe_mis=0.89 oe_lof=0.18)								
chr9	128424504	128424504	C	T	0.3904	1766	0.00e+00	4524	0.38647	2286	1440	863-903-1353-1405	CCTTGCATCCC	false		QUAL=255										0.05095		130,			5.1460	15.48				CERCAM|0.01|0.00|0.00|0.00|18|48|-2|0		0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					CERCAM (inh=n/a oe_syn=0.91 oe_mis=0.98 oe_lof=0.52)								
chr10	71362156	71362156	A	G	0.7760	3101	0.00e+00	3996	0.77658	727	2527	1515-1586-458-437	CCGCCATCTGC	false	off-target	QUAL=255						130347 [benign DISEASE=Histiocytosis-lymphadenopathy plus syndrome,not specified];				0.87443		12044,			-0.5760	0.01				SLC29A3|0.01|0.00|0.00|0.00|-16|30|30|-25		0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					SLC29A3 (inh=AR oe_syn=1.17 oe_mis=1.08 oe_lof=0.82)	SLC29A3	COSV64386549			Other			
chr10	71362188	71362188	T	C	1.0000	4003	0.00e+00	4003	1.00000	0	3275	1928-2075-0-0	AAGGGTTCGGG	false		QUAL=255						130337 [benign DISEASE=Histiocytosis-lymphadenopathy plus syndrome,not specified];				0.84544		11319,			0.3380	2.15				SLC29A3|0.00|0.00|0.00|0.00|45|-2|23|-2		0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					SLC29A3 (inh=AR oe_syn=1.17 oe_mis=1.08 oe_lof=0.82)	SLC29A3	COSV64385266			Other			
chr11	64434167	64434167	C	T	0.7262	2247	0.00e+00	3094	0.72394	686	1799	1269-978-466-381	GGTGACCCATA	false		QUAL=255										0.50440		4011,			0.5090	4.41						0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)													
chr11	115336425	115336425	C	G	0.2387	635	0.00e+00	2660	0.23360	1624	495	349-286-1139-885	ACTTTCAATTT	false	off-target	QUAL=255										0.02093		4,			-2.5440	10.69				CADM1|0.00|0.00|0.00|0.00|-24|-38|-15|33		0		0			0	0	0	0 / 0					CADM1 (inh=n/a oe_syn=1.14 oe_mis=0.67 oe_lof=0.19)								
chr11	115336457	115336457	C	G	1.0000	2684	0.00e+00	2684	1.00000	0	2144	1267-1417-0-0	ACCGACTGCCA	false		QUAL=255										0.62674		6233,			-0.8710	0.14				CADM1|0.00|0.00|0.00|0.00|35|-1|43|1		0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					CADM1 (inh=n/a oe_syn=1.14 oe_mis=0.67 oe_lof=0.19)								
chr13	99385979	99385979	A	G	0.6178	1311	0.00e+00	2122	0.61409	663	1055	630-681-431-380	TATCCAGAGTT	false		QUAL=255										0.63581		6386,			-0.1150	11.25						0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					UBAC2 (inh=n/a oe_syn=0.89 oe_mis=0.68 oe_lof=0.37)								
chr13	99386017	99386017	A	T	0.6144	1359	0.00e+00	2212	0.61327	688	1091	701-658-454-399	TGGAGAAGAAC	false	off-target	QUAL=255										0.63737		6415,			0.3790	1.97						0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					UBAC2 (inh=n/a oe_syn=0.89 oe_mis=0.68 oe_lof=0.37)								
chr14	62283828	62283828	C	T	0.7958	2720	0.00e+00	3418	0.79135	574	2177	1343-1377-346-351	ATTCTCAGAAG	false	Clustered_Variant	QUAL=255										0.53217		4495,			-1.0290	7.64						0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)													
chr15	79523815	79523815	G	A	0.4569	1419	0.00e+00	3106	0.46120	1361	1165	612-807-867-820	CCAGTGTCCAC	false		QUAL=255										0.53646		4534,			1.1340	3.53						0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)													
chr17	50356597	50356597	T	C	0.4737	1655	0.00e+00	3494	0.46963	1493	1322	830-825-891-948	CTGTATGGCAG	false		QUAL=255							CM064363 [CLASS=DP MUT=ALT PHEN="Organ involvement in PXE association with" GENE=XYLT2];			0.44454		3189,			-2.5780	8.75				XYLT2|0.00|0.02|0.00|0.00|-32|6|-4|-30		2	Leuk,eMed-HCC	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					XYLT2 (inh=AR oe_syn=1.02 oe_mis=0.75 oe_lof=0.17)	XYLT2	COSV50017488			Other			
chr17	82504059	82504059	C	T	0.4951	1528	1.41e-56	3086	0.49623	1269	1250	802-726-827-731	CTCCCCGGCTG	false	Low_Complexity;Clustered_Variant	QUAL=255										0.29340		1388,			-0.1210	1.04						0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)													
chr18	9749882	9749882	G	A	0.4936	1653	0.00e+00	3349	0.49706	1369	1353	852-801-851-845	TATGGGTTGCC	false		QUAL=255										0.44132		3063,			0.2430	5.46				RAB31|0.00|0.00|0.00|0.00|16|7|22|-1		4	PATHO_Somatic	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					RAB31 (inh=n/a oe_syn=0.62 oe_mis=0.65 oe_lof=0.57)								
chr19	46674656	46674656	G	A	1.0000	3240	0.00e+00	3240	1.00000	0	2666	1571-1669-0-0	AGCGCACGTCG	false	Clustered_Variant	QUAL=255										0.99949		15633,			3.1600	20.50				PRKD2|0.00|0.00|0.00|0.00|49|-14|10|2		0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					DACT3-AS1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a):PRKD2 (inh=n/a oe_syn=1.03 oe_mis=0.57 oe_lof=0.07)	PRKD2	COSV52188687	lung/carcinoma/non_small_cell_carcinoma=6/6=100%;lung/carcinoma/squamous_cell_carcinoma=43/50=86%;lung/carcinoma/large_cell_carcinoma=5/11=45.45%;lung/carcinoma/adenocarcinoma=33/39=84.62%		Other			
chr19	49401772	49401772	T	C	0.2405	755	0.00e+00	3139	0.24218	1937	619	354-401-1180-1204	CTTTGTCCTAC	false		QUAL=255										0.52130		4237,			-0.9280	11.08				CCDC155|0.00|0.00|0.00|0.00|-1|14|-10|-23		0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					KASH5 (inh=n/a oe_syn=0.77 oe_mis=0.81 oe_lof=0.55)								
chr20	63540916	63540916	C	A	0.5814	2464	0.00e+00	4238	0.58099	1472	2041	1121-1343-844-930	GAGCACGTAGA	false	off-target	QUAL=255										0.14218		751,			-2.5750	0.42				SRMS|0.00|0.00|0.00|0.00|-15|5|44|1		0		0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)					PTK6 (inh=n/a oe_syn=1.08 oe_mis=0.93 oe_lof=0.92):SRMS (inh=n/a oe_syn=0.93 oe_mis=1.00 oe_lof=1.03)	SRMS	COSV53916588			Other			
chr22	33163522	33163522	T	A	0.9989	2820	0.00e+00	2823	1.00000	0	2295	1392-1428-0-3	CACCCTTGTAG	false		QUAL=255										0.45736		3207,			-0.0600	4.62						2	PATHO_Somatic	0			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)													
